Corcept insider plans Rule 144 sale of 20,000 shares

Corcept Therapeutics insider William Guyer has filed to sell 20,000 shares of common stock under Rule 144.

Rhea-AI Filing Summary

Corcept Therapeutics insider William Guyer has filed to sell 20,000 shares of common stock under Rule 144. The planned sale, through broker Stifel Nicolaus & Company on NASDAQ, has an aggregate market value of $814,200.00, with 105,190,000 shares of the issuer’s common stock outstanding.

The shares to be sold were acquired on 02/03/2026 via a stock option exercise paid in cash on the same date. Over the past three months, Guyer has sold 20,000 shares on each of three occasions, for gross proceeds of $1,601,525.00, $703,655.00, and $1,507,121.00.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Rule 144 filing by Corcept Therapeutics (CORT) insider disclose?

The filing discloses that insider William Guyer intends to sell 20,000 Corcept Therapeutics common shares under Rule 144. The planned sale has an aggregate market value of $814,200.00 and will be executed through Stifel Nicolaus & Company on the NASDAQ exchange.

How many Corcept Therapeutics (CORT) shares is William Guyer planning to sell?

William Guyer plans to sell 20,000 shares of Corcept Therapeutics common stock. These shares have an aggregate market value of $814,200.00 based on the filing and are to be sold on NASDAQ through broker Stifel Nicolaus & Company Inc.

How were the Corcept Therapeutics (CORT) shares in this Rule 144 notice acquired?

The 20,000 Corcept Therapeutics common shares were acquired on 02/03/2026 via a stock option exercise. The filing states that 20,000 securities were acquired from Corcept Therapeutics Inc., with cash payment made on the same date as the option exercise.

What prior Corcept Therapeutics (CORT) share sales has William Guyer reported?

Over the past three months, William Guyer reported three sales of 20,000 Corcept Therapeutics common shares each. These occurred on 11/05/2025, 12/02/2025, and 01/06/2026, generating gross proceeds of $1,507,121.00, $1,601,525.00, and $703,655.00, respectively.

How many Corcept Therapeutics (CORT) shares are outstanding according to the filing?

The filing states that 105,190,000 shares of Corcept Therapeutics common stock are outstanding. This figure provides context for the planned 20,000-share Rule 144 sale disclosed for William Guyer, showing the sale relative to the company’s total common shares.

Which broker and exchange are involved in the Corcept Therapeutics (CORT) Rule 144 sale?

The planned 20,000-share sale will be executed through Stifel Nicolaus & Company Inc. The filing identifies NASDAQ as the securities exchange where the Corcept Therapeutics common shares are to be sold under this Rule 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 11:26 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001879013
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INC
SEC File Number	000-50679
Address of Issuer	101 REDWOOD SHORES PARKWAY REDWOOD CITY CALIFORNIA 94065
Phone	650.688.8803
Name of Person for Whose Account the Securities are To Be Sold	Guyer William
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Company Inc. 501 N. Broadway St. Louis MO 63102	20000	814200.00	105190000	02/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/03/2026	Stock Option Exercise	Corcept Therapeutics Inc.			20000	02/03/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	12/02/2025	20000	1601525.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	01/06/2026	20000	703655.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	11/05/2025	20000	1507121.00

144: Remarks and Signature

Remarks
Date of Notice	02/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/27/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Toni Dobel, as a duly authorized representative of STIFEL, as attorney-in-fact for William Guyer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)